CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis
CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis Print Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to prevent or reverse life-threatening opioid-related side effects, according to a news release. A recent study by medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain reli...